Safety of a rapid outpatient hydration protocol for patients with renal impairment requiring intravenous iodinated contrast media for CT

Nicole Kessa Wee¹, MBBS, FRCR, Siew Ching Tiong¹, MBBS, FRCR, Chau Hung Lee¹, MBBS, FRCR, Martin Weng Chin H’ng¹, MBBS, FRCR

¹Department of Diagnostic Imaging, Tan Tock Seng Hospital, Singapore

Correspondence: Dr Nicole Kessa Wee, Senior Resident, Department of Diagnostic Imaging, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433. nicolekessa.wee@mohh.com.sg
ABSTRACT

Introduction: Patients receiving intravenous iodinated contrast media (IOCM) for CT are predisposed to contrast-induced nephropathy. Chronic kidney disease is an important risk factor, and hydration is the mainstay of prevention. While inpatients can undergo intravenous hydration, there is a knowledge deficit regarding regimens for outpatients. We employed a rapid outpatient hydration protocol to reduce postponement of scan appointments for patients with suboptimal estimated glomerular filtration rate (eGFR).

Methods: From June 2015, we amended our CT preparation protocol to mandate rapid hydration (oral, intravenous or both) for patients with an eGFR of 30–60 mL/min/1.73 m². Patients receiving this hydration protocol from June to November 2015 were followed up for one month to monitor any admissions for fluid overload, and up to one year to determine the long-term effect on eGFR.

Results: 226 outpatients received the hydration protocol, which correlated with a 95% reduction in postponement of imaging appointments. No complications of fluid overload from hydration were encountered. There was a significant association between age and decrease in eGFR, but this was not significant when stratified by drop in eGFR category. No statistical significance was found between decrease in eGFR and gender or race. Higher baseline eGFR was less likely to be associated with decrease in eGFR after imaging. Type of hydration was not related to a drop in eGFR category for patients with eGFR of 45–59 mL/min/1.73 m².

Conclusion: We defined a shorter hydration regimen that is safe to use in the outpatient setting.

Keywords: chronic kidney disease, contrast induced nephropathy, hydration, iodinated contrast media, renal impairment
INTRODUCTION

Computed tomography (CT) is one of the most commonly utilised radiological modalities in the imaging of structures within the human body, given its high spatial resolution and rapid image acquisition. In CT, intravenous iodinated contrast media (IOCM) is often used to enhance the visibility of internal organs and pathology. Patients receiving intravenous IOCM for their CT imaging are predisposed to contrast-induced nephropathy (CIN). Impairment of renal function is reflected in the glomerular filtration rate (GFR), although there is no way of measuring this. Instead, surrogate measures such as serum creatinine and estimated glomerular filtration rate (eGFR) are used, but they have their drawbacks.

Although serum creatinine is the most commonly used measure of renal function, it has limitations as an accurate measure of GFR. Serum creatinine is considerably influenced by the patient’s gender, muscle mass, nutritional status and age. Test results can be normal even if GFR is abnormal, up to a reduction in GFR of nearly 50%. This is because serum creatinine levels lag behind changes in renal function. (1) Although eGFR is more accurate than serum creatinine, its formula also relies in part on serum creatinine levels. Furthermore, eGFR determinations were created from studies on narrow populations and individuals at a stable level of renal function, and not patients who are in an unsteady state, as they may be when being admitted. (2) As such, eGFR values will not be accurate at approximately the time after IOCM administration when GFR is expected to fluctuate.

After IOCM, serum creatinine usually begins to rise within 24 hours, peaks within four days and returns to baseline within 7–10 days. (3) Diagnosis of CIN can be defined as a 25% increase in serum creatinine from baseline or 0.5 mg/dL rise in absolute creatinine over 48–72 hours. (3) It is unusual for patients to progress to acute kidney injury (AKI) or develop permanent renal dysfunction. (4) However, few studies have followed patients for more than 72 hours. (5)
The incidence of CIN ranges from 0% to 24%, varying widely depending on risk factors.(3) One important risk factor for CIN is having chronic kidney disease (CKD).(3,5,6) Compared to serum creatinine-based thresholds, eGFR thresholds (Table I)\(^7\) are more accurate in predicting this risk.(8) Interestingly, while the American College of Radiology guidelines on contrast media does not indicate a specific eGFR threshold below which there is increased risk of CIN, the European Society of Urogenital Radiology specifies a threshold of 45 mL/min/1.73 m\(^2\), below which CIN prophylaxis should be instituted.(5,9) At our institution, we defined CKD as having an eGFR < 60 mL/min/1.73 m\(^2\).(10)

<table>
<thead>
<tr>
<th>Table I. Classification of chronic kidney disease (CKD)(^7)</th>
<th>Range (mL/min/1.73 m(^2))</th>
<th>CKD category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal and high</td>
<td>(\geq 90)</td>
<td>G1</td>
</tr>
<tr>
<td>Mild reduction</td>
<td>60–89</td>
<td>G2</td>
</tr>
<tr>
<td>Mild-moderate reduction</td>
<td>45–59</td>
<td>G3a</td>
</tr>
<tr>
<td>Moderate-severe reduction</td>
<td>30–44</td>
<td>G3b</td>
</tr>
<tr>
<td>Severe reduction</td>
<td>15–29</td>
<td>G4</td>
</tr>
<tr>
<td>Kidney failure</td>
<td>&lt; 15</td>
<td>G5</td>
</tr>
</tbody>
</table>

With regard to the lower limit at which contrast should be avoided unless the benefits outweigh the risks of CIN, there are now two large propensity score-adjusted studies. One showed no risk of CIN from IOCM, regardless of baseline eGFR,\(^11\) while another reveals that patients with an eGFR < 30 mL/min/1.73 m\(^2\) are at significant risk (and those with eGFR 30–44 mL/min/1.73 m\(^2\) are borderline but do not have a statistically significant risk).\(^12\) Hence, a lower limit of 30 mL/min/1.73 m\(^2\) appears most appropriate.\(^5\)

As there is no definitive treatment for AKI, prevention of CIN is crucial.\(^3\) Intravenous physiological saline is the established prophylaxis for CIN in CKD patients.\(^5,9,13-15\) A popular regimen is normal saline infused at 1 mL/kg/h for 6–12 hours before the procedure and continued for 6–12 hours afterwards.\(^3\) Another possible protocol would be 0.9% saline at 100 mL/h, beginning 6–12 hours before and continuing 4–12 hours after, but this is only practical
in the inpatient setting.\(^{(5)}\) Two regimens have been reported – a standard protocol (0.9% normal saline at 3–4 mL/kg/h for four hours before and after contrast administration) and a long protocol (0.9% normal saline at 1 mL/kg/h for 12 hours before and after contrast administration).\(^{(2)}\) For same-day infusion, normal saline is infused at 3 mL/kg/h for at least one hour before the procedure and six hours afterwards.\(^{(4)}\) Isotonic fluids are preferred (Lactated Ringer’s or 0.9% normal saline), but the ideal infusion rate and volume are unknown.\(^{(5)}\)

These proposed regimens involve long periods of infusion, suitable for inpatients. However, there is a gap in knowledge for administering hydration in the outpatient setting. Hydrating outpatients would likely entail a more rapid rate given the constraints of time and space. A report by Hossain discusses barriers to implementing hydration from several perspectives.\(^{(3)}\) Issues pertinent to us are lack of space for infusing, time and manpower required for monitoring, and a suitable billing charge for providing this adjunct service.\(^{(3,6,14)}\)

Given the controversies regarding the degree of renal impairment at which there is increased risk of CIN and the potential limitations of hydration in an outpatient setting, the aims of our study were twofold. The primary aim was to ensure safety of a rapid outpatient hydration protocol in the local setting of a tertiary hospital, thereby reducing postponements. Our secondary aim was to find out if there is long-term impact on renal function beyond the expected duration of CIN (characterised by a statistically significant change in absolute eGFR values as well as eGFR categories), which could be affected by individuals’ demographics, baseline renal function and type of hydration.

**METHODS**

We conducted a retrospective review of secondary data of patients receiving hydration over a six-month period from June to November 2015, which was collected as part of quality improvement. All data had been collected on hard copies and filed. This included patients’
details, baseline eGFR, method of hydration, any admissions for fluid overload and follow-up eGFR levels. The data was tabulated in Microsoft Excel 2003.

Prior to 2015, our institution had followed a protocol for outpatients with intermediate risk (eGFR 30–60 mL/min/1.73 m²) who required IOCM for their CT (Box 1). In patients with eGFR < 30 mL/min/1.73 m², intravenous contrast is a contraindication and the issue of hydration would not arise.

**Box 1. Protocol for outpatients with intermediate risk:**

**Hydration component**
- Water (drinking 8 cups of water [250 mL/cup] per day) or
- Intravenous hydration 250 mL (via fast drip) just before and after the study

**N-acetylcysteine component**
- Effervescent tablet 600 mg 12 hourly × 4 doses (3 before scan, 1 after)

Note: For patients on fluid restriction, the ordering clinician was to discuss the case with the radiologist.

Since N-acetylcysteine (NAC) was cost-effective and potentially beneficial with no adverse effects, it was recommended as part of the renal protective regimen.(3) The option of hydration was already in place but greatly underutilised. Only a minority of patients underwent intravenous hydration that required insertion of a cannula. Also, the definition of ‘fast drip’ was not clearly specified and carried a risk for patients on fluid restriction. Thus, it was easier to encourage patients to consume NAC orally, albeit with improper supervision and follow-up on the actual volume. Publications from 2014 to 2015 showed less support for the efficacy of NAC in the prevention of CIN.(3-6) Non-prescription of this medication by referring clinicians led to frequent postponements and rescheduled scans. A consensus was reached among the main referring disciplines of the hospital, with the primary intention of reducing the postponement rate and inconvenience for the patient and carer as part of quality improvement.
From June 2015, the CT preparation protocol was amended to make NAC optional. With the exclusion of NAC, we were compelled to adhere more closely to hydration, in particular via the intravenous route. The details and effects of hydration had hitherto been unproven.\(^{(14,15)}\) Radiology trainees were tasked to screen for patients who might have undiagnosed renal dysfunction, counsel those with risk factors for CIN, employ a suitable hydration protocol for this group of patients and to follow up for any adverse outcome, particularly admissions for fluid overload.

For patients at risk, eGFR was traced. Those who did not have a baseline eGFR were offered point-of-care testing (POCT) on the day of their scan at a small cost, using the i-STAT® 1 Analyser MN:300 (Abbott Point of Care Inc, Abbott Park, IL, USA) device. The result of the POCT creatinine test is displayed in mol/L. This had to be converted to an eGFR value. Even prior to this study, our department had been using the online eGFR calculator available from the St George’s University of London website.\(^{(10)}\) This calculator estimates eGFR based on the four-item Modification of Diet in Renal Disease (MDRD) formula: creatinine, age, gender and ethnicity.\(^{(10)}\)

Thereafter, a suitable type of hydration was employed. For those with a poorer eGFR of 30–44 mL/min/1.73 m\(^2\), intravenous infusion of 250 mL of normal saline pre-scan and another 250 mL post scan over half an hour each was recommended. Those with a better eGFR of 45–60 mL/min/1.73 m\(^2\) received a 500-mL bottle of mineral water and were encouraged to consume as much as possible prior to the scan and to finish the remainder after the scan, before leaving the department. An oral-intravenous combination was permitted to make up the 500 mL. This was applicable to patients requiring CT of the abdomen and pelvis who needed to drink fluids to fill the bowel loops as a type of contrast agent. The doctor decided on the ratio of the oral route to the intravenous route depending on the patient’s tolerability to either. Care was taken for those with risks of fluid overload, including but not limited to cardiac and renal
failure. We deemed that most patients would be under-hydrated due to the need to fast for at least three hours before CT.

Given the space and manpower constraints, we decided to undertake infusion within the department. This also permitted close supervision of the patient to ensure that the necessary volume had been consumed. The patient then went for the scan. The contrast medium was low-osmolar iohexol 350, and the volume varied between 50 mL and 120 mL.

The rapidity of the infusion was an initial concern. Patients who had received hydration were followed up for one month to see if they had been admitted for fluid overload. Any eGFR test performed within this period was also noted. In patients whose eGFR was still not measured within the month, their earliest legitimate follow-up eGFR was retrieved from our hospital records within one year of CT. If this reading was not available, a creatinine value during a period of stability (e.g., close to the end of an admission) was used and converted to eGFR using the same calculator. The hospital laboratory also calculates eGFR using an MDRD formula that we acknowledge to be more accurate.\(^{(10)}\) When it was available, we prioritised the laboratory result over our derived one.\(^{(10)}\)

Regarding the determination of the category of CKD, our laboratory was not able to provide exact values whenever the eGFR was \(> 60 \text{ mL/min/1.73 m}^2\) or \(< 30 \text{ mL/min/1.73 m}^2\), which was a limitation. Thus, we did not treat eGFR as a continuous variable, but considered it in terms of whether it decreased or not. Similarly, we were unable to differentiate between CKD category G1 and G2 as well as between category G4 and G5. For practical purposes, we also evaluated CKD categories according to whether there was a decrease.

Statistical analyses were performed using IBM SPSS Statistics version 25.0 (IBM Corp, Armonk, NY, USA) after data was anonymised. Student’s \(t\)-test was used to analyse continuous variables and Fisher’s exact test was applied to categorical variables. The study was approved by our institution’s Domain Specific Review Board.
RESULTS

Fig. 1 shows an overview of our study. A total of 261 outpatients were receiving hydration during this period (mean 44 patients/month), which made up 3.3% of the total number of outpatient scans. 35 patients were excluded for the following reasons: no baseline eGFR (n = 3), no follow-up eGFR (n = 28), eGFR of ≥ 60 mL/min/1.73 m² and still opting for hydration (n = 2), and hydrated but eventually undergoing CT without IOCM (n = 2). The remaining 226 patients were included (Table II).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age* (yr)</td>
<td>71.5 (26.0–90.0)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>124 (54.9)</td>
</tr>
<tr>
<td>Female</td>
<td>102 (45.1)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td>198 (87.6)</td>
</tr>
<tr>
<td>Malay</td>
<td>17 (7.5)</td>
</tr>
<tr>
<td>Indian</td>
<td>6 (2.7)</td>
</tr>
<tr>
<td>Others</td>
<td>5 (2.2)</td>
</tr>
</tbody>
</table>

*Data presented as mean (range).

There were no complications of fluid overload from hydration. Only six cases were postponed over these six months, as compared to 119 cases in the preceding six months or 106 in the same period the year before. 73.5% of patients had their baseline eGFR assessed within six months prior to their CT scan. Another 15.9% required POCT on the same day. The remaining 10.6% had their eGFR measured more than six months before the scan. 15.9% of the patients had a follow-up eGFR measurement by 10 days. By six months, 85.8% of the patients had eGFR readings; the remaining 14.2% had their follow-up test at the end of one year.

The mean age of the 138 patients who did not show a decrease in eGFR was 70.4 ± 10.4 years, while that of the 88 patients who experienced a decrease was 73.2 ± 9.7 years, and
the difference was statistically significant (p = 0.047). Despite the significant decrease in eGFR, we considered that using a drop in eGFR category as an indicator was more practical, as management of a patient only changes along with a change in eGFR category. The mean age of the 195 patients who did not show a drop in eGFR category was 71.1 ± 10.3 years, whereas that of the 31 patients who did was 73.9 ± 9.2 years. There was no significant difference between these groups (p = 0.134). When 60 years, 70 years and 75 years were used as cut-off values for age, the p-values were not statistically significant at 0.081, 0.264 and 0.493, respectively. There was also no statistical significance between decrease in eGFR and gender (p = 0.085) and race (p = 0.156).

Table III shows the general trend of a higher mean baseline eGFR being associated with less of a drop in the follow-up eGFR category. In both the G3a and G3b groups, there was a statistically significance difference in baseline eGFR between the group that had a drop in their eGFR category and the group that did not (p = 0.000).

<table>
<thead>
<tr>
<th>Baseline eGFR category</th>
<th>Follow-up eGFR category</th>
<th>No.</th>
<th>Mean baseline eGFR (mL/min/1.73 m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G3a, mild-moderate reduction (n = 160)</td>
<td>No drop</td>
<td>135</td>
<td>52.8</td>
</tr>
<tr>
<td></td>
<td>Drop</td>
<td>25</td>
<td>48.6</td>
</tr>
<tr>
<td>G3b, moderate-severe reduction (n = 66)</td>
<td>No drop</td>
<td>60</td>
<td>40.0</td>
</tr>
<tr>
<td></td>
<td>Drop</td>
<td>6</td>
<td>33.8</td>
</tr>
</tbody>
</table>

Hydration was most frequently either oral (44.7%) or intravenous (46.9%), followed by the oral-intravenous combination (8.4%), as shown in Table IV. The oral route was preferred for those with less severe CKD (mean eGFR 53.5 mL/min/1.73 m²) as opposed to intravenous for more severe CKD (mean eGFR 43.8 mL/min/1.73 m²) and the oral-intravenous combination for intermediate severity (mean eGFR 47.0 mL/min/1.73 m²).
Table IV. Change in baseline estimated glomerular filtration rate (eGFR) category at follow up based on choice of hydration.

<table>
<thead>
<tr>
<th>Baseline eGFR category</th>
<th>Oral (n = 101)</th>
<th>Oral and intravenous (n = 19)</th>
<th>Intravenous (n = 106)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No drop</td>
<td>Drop</td>
<td>No drop</td>
</tr>
<tr>
<td>G3a, mild-moderate reduction</td>
<td>91</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>G3b, moderate-severe reduction</td>
<td>1</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>

For the G3a group, there was a statistically significant association between type of hydration and change in eGFR category (p = 0.005); those receiving intravenous hydration showed a significant drop in their eGFR category. This was surprising, as intravenous hydration was expected to be more effective than the oral route, which has unreliable absorption and effectiveness.\(^{(3-6)}\)

Given that the mean eGFR of the G3a group was 52.13 mL/min/1.73 m\(^2\), we stratified this group into two subgroups, one with better renal function (eGFR 53–59 mL/min/1.73 m\(^2\)) and another with poorer renal function (eGFR 45–52 mL/min/1.73 m\(^2\)). Chi-square test was repeated and showed no significant difference, with p-values of 0.546 and 0.111, respectively. Hence, the apparently worse outcome of intravenous hydration was more likely due to the fact that those receiving it had inherently poorer renal function to begin with. This test was not performed for those in the G3b group, as the numbers were small.

**DISCUSSION**

IOCM used in CT carries the risk of CIN in patients with predisposing factors.\(^{(16)}\) CIN is defined as acute deterioration in renal function within 48–72 hours of IOCM administration, with pre-existing CKD and concomitant diabetes mellitus being important risk factors.\(^{(3-6)}\) Other risk factors include a dehydrated state, usage of a large volume of high-osmolarity IOCM or nephrotoxic medications and advanced age.\(^{(3)}\) Risk of CIN is reduced by peri-procedural hydration, using low- or iso-osmolar intravenous IOCM and discontinuation of nephrotoxic
drugs.(17-19) Intravenous hydration is the most important intervention, while premedication with reno-protective agent NAC has fallen out of favour.(3-6)

The literature appears to suggest that oral hydration is not inferior to established intravenous hydration in prevention of CIN.(20,21) One potential outpatient hydration protocol included an intravenous bolus of 500 mL of normal saline before contrast administration and oral hydration more than eight hours after contrast administration.(22) Therefore, in mid-2015, our department implemented a rapid outpatient hydration protocol comprising either oral or intravenous peri-procedural hydration. This protocol was reserved for outpatient scans of patients with pre-existing renal impairment (defined as eGFR < 60 mL/min/1.73 m²) who were not premedicated with NAC (which had been made optional). Under this protocol, the scan was still performed, with the patient receiving peri-procedural hydration intravenously or orally half to one hour before and after the scan.

Implementation and evaluation of the effectiveness of the rapid outpatient hydration protocol in reducing CIN was challenging. Firstly, most established hydration protocols required continuous infusion over 24 hours peri-procedurally, making these only possible for inpatients, although a shortened duration over 6–7 hours has been proposed.(2,4) There is still a knowledge gap in the literature regarding the effectiveness of hydration protocols that would be applicable in the outpatient setting. Secondly, monitoring for CIN required trending of serum creatinine at 72 hours and 10 days after imaging, which would also be impractical for outpatients. Therefore, it would be more practical and more clinically relevant to assess the impact of our hydration protocol on renal function in the long term. We performed this by following up on the eGFR of all included patients over the course of one year. The study endpoint would then be suitable for determining if outpatients with pre-existing renal impairment who were not premedicated with NAC, and who would otherwise have had their scans postponed, could be safely imaged with this new protocol. Our main concerns were
immediate complications, particularly that of fluid overload, as well as long-term impact on renal function in patients with pre-existing renal impairment.

Over the first six months of the implementation of the rapid outpatient hydration protocol, only six outpatient scans were postponed. This represented a 95% reduction in scan postponement. Furthermore, there were no complications of fluid overload from hydration. Although complication from intravenous hydration has been cited elsewhere,\(^\text{13,14}\) this issue did not arise in our patients, who were all outpatients and may have fasted up to three hours beforehand, rendering them relatively under-hydrated.

Although our study suggested that having advanced age was likely to cause a reduction in eGFR, this became statistically insignificant when it was correlated with a drop in eGFR category. Although different guidelines have proposed varying cut-off ages of 60, 70 and 75 years for when an individual would be at risk for CIN,\(^\text{4,5}\) we found no evidence of this in our study. Our study also showed that change in eGFR was not significantly affected by gender or race.

Having a higher baseline eGFR, implying better renal function, may safeguard a patient from experiencing a drop in eGFR category. Within groups G3a and G3b, this mean baseline eGFR was 52.8 mL/min/1.73 m\(^2\) and 40.0 mL/min/1.73 m\(^2\), respectively.

Our study also showed that change in eGFR category was not affected by route of hydration (for the G3a group). This is consistent with reports in the literature that hydration may not be necessary for those with an eGFR of 45–59 mL/min/1.73 m\(^2\) receiving intravenous IOCM.\(^\text{4}\) The initial and apparently worse outcome of intravenous hydration when compared to oral hydration was more likely to be due to this cohort of patients having inherently poorer renal function to begin with. They were then given intravenous rather than oral hydration with the assumption that the former would be more effective.\(^\text{3-6}\)
Based on the first, single post-CT eGFR value, 31 patients showed a drop in at least one eGFR category from their baseline. None of these patients received cumulative doses of IOCM over the course of one year in the form of multiple CT scans or angiography procedures that could have contributed to progressive chronic renal impairment. In 24 of these patients, the eGFR eventually recovered to the baseline category. The seven patients who showed no improvement had significant comorbidities (e.g. hypertension, diabetes mellitus and ischaemic heart disease) that could potentially have contributed to the progression. These had not been considered and were one limitation of the study. Provided that these patients remained stable, a longer follow-up period may be better to determine if their eGFR gradually trended back towards baseline.

There is little evidence that IOCM is an independent risk factor for AKI in patients with eGFR $\geq 30$ mL/min/1.73 m$^2.$ Recent evidence suggested that there might be no significant difference in the incidence of CIN and contrast-independent acute renal impairment in patients with pre-existing renal impairment. In line with our findings, we incidentally discovered two patients who received the hydration protocol, then eventually underwent non-contrast CT. One showed no drop in eGFR, while the other dropped one category following CT.

Our study had other minor limitations. Firstly, different methods were used to derive the baseline eGFR. In some patients, the creatinine value was derived from POCT and then converted to eGFR using an online calculator. To minimise any discrepancy, priority was given to the value from the laboratory.

Secondly, baseline eGFR was taken at different times. The maximum acceptable interval between baseline renal function assessment and contrast medium administration in at-risk patients has not been ascertained and can be up to six months. Progressive deterioration in renal function may be ongoing between acquisition of baseline eGFR and imaging, exaggerating the results of patients with a decrease in eGFR or a drop in eGFR category. In
addition, follow-up eGFR values were also obtained at different times. However, our main aim was to evaluate safety based on whether any patient had been admitted for complications and long-term impact on renal function, and not to plot the acute rise-drop of creatinine that suggests CIN. We only considered a single follow-up eGFR result, as we were not overly concerned with the trend of development and normalisation of eGFR, but rather whether there was a change in absolute eGFR reading or change in category. Given the single reading, the absolute decrease was not as relevant, because a follow-up test might reveal normalisation. Therefore, more emphasis was placed on a drop in category, as this would affect management.

Finally, we acknowledge that this study was limited to hydration status and underlying renal function as risk factors for long-term eGFR decline. Other confounders such as concomitant diseases, both acute and chronic, and the primary cause for renal impairment were not studied, and may thus impair the conclusions stated.

In conclusion, our institution’s rapid outpatient hydration protocol has delineated a shorter period of hydration that is safe to use in the outpatient setting. This will alleviate patient and carer inconvenience, reduce expenditure and free up slots to accommodate more acute inpatients by avoiding rescheduling of postponed cases.

ACKNOWLEDGEMENTS

We would like to thank Mr Joshua Wong Guo Xian, Senior Medical Statistician, Office of Clinical Epidemiology, Analytics and Knowledge, Tan Tock Seng Hospital, Singapore, for advice and help with the statistics.
REFERENCES


FIGURE

261 patients

Excluded (n = 35)

226 patients

G3a (n = 160)

• Oral hydration (n = 100)
  - No drop (n = 91)
  - Drop (n = 9)
• Oral and intravenous hydration (n = 13)
  - No drop (n = 10)
  - Drop (n = 3)
• Intravenous hydration (n = 47)
  - No drop (n = 34)
  - Drop (n = 13)

G3b (n = 66)

• Oral hydration (n = 1)
  - No drop (n = 1)
• Oral and intravenous hydration (n = 6)
  - No drop (n = 6)
• Intravenous hydration (n = 59)
  - No drop (n = 53)
  - Drop (n = 6)

• No baseline eGFR (n = 3)
• No follow-up eGFR (n = 28)
• eGFR ≥ 60 mL/min/1.73 m² (n = 2)
• eGFR 30–60 mL/min/1.73 m² and hydrated, but eventually did not require contrast (n = 2)

Fig. 1 Flowchart shows overview of the study. eGFR: estimated glomerular filtration rate